• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

November 17, 2023 by Deborah Bloomfield

The world’s first CRISPR-based therapy has been approved by the UK medicines regulator, it was announced on Thursday. The pioneering treatment, which involves the much-lauded gene-editing method CRISPR, will target two blood conditions: sickle-cell disease and beta-thalassemia.

“This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases,” Kay Davies, a professor of anatomy at the University of Oxford, told the Science Media Centre.

Advertisement

According to an announcement from the medicine’s manufacturers, Vertex Pharmaceuticals and CRISPR Therapeutics, the treatment, called CASGEVY, has been authorized for certain sickle-cell disease or beta thalassemia patients aged 12 and up – around 2,000 people in the UK will be eligible to receive it.

It is thought that the US will soon follow suit, with the Food and Drug Administration expected to approve the therapy for sickle-cell patients in December and for beta-thalassemia patients next March.

Casgevy is based on the CRISPR-Cas9 gene editing system that revolutionized the field of genome engineering when its discovery was announced back in 2012. Since then, it’s been used in all manner of research, in our species and others, winning its developers a Nobel Prize in 2020.

“I am excited and a bit overwhelmed with emotion at the news of the approval of CASGEVY in the UK. Going from the lab to an approved CRISPR therapy in just 11 years is a truly remarkable achievement,” one of the system’s developers, Jennifer Doudna, said of the latest breakthrough.

Advertisement

“I am especially pleased that the first CRISPR therapy helps patients with sickle cell disease, a disease that has long been neglected by the medical establishment. This is a win for medicine and for health equity.”

Sickle-cell disease and beta-thalassemia are caused by errors in genes that code for hemoglobin – the protein in red blood cells that delivers oxygen to our tissues. 

CASGEVY makes use of the CRISPR-Cas9 system to edit a gene called BCL11A, which normally prevents production of a type of fetal hemoglobin. In doing so, it disrupts that gene, meaning the hemoglobin, which is free of the abnormalities associated with sickle-cell disease and beta-thalassemia, can be produced.

When gene-edited cells are then infused back into patients, they mature into red blood cells that contain fetal hemoglobin, and therefore boost oxygen supply to the tissues and alleviate patients’ symptoms.

Advertisement

The treatment’s approval comes off the back of promising clinical trial results, which identified no serious safety issues. However, some experts have raised potential concerns.

“It is well known that CRISPR can result in spurious genetic modifications with unknown consequences to the treated cells,” Professor David Rueda of Imperial College London told the Science Media Centre. “It would be essential to see the whole-genome sequencing data for these cells before coming to a conclusion. Nonetheless, this announcement makes me feel cautiously optimistic.”

It’s also likely to cost a lot – a price has not yet been set in the UK – which, unfortunately, will limit its reach.

“The challenge is that these therapies will be very expensive so a way of making these more accessible globally is key,” Davies added.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Soccer – FIFA backs down on threat to fine Premier clubs who play South American players
  2. U.S. House passes abortion rights bill, outlook poor in Senate
  3. Two children killed in missile strikes on Yemen’s Marib – state news agency
  4. We’ve Breached Six Of The Nine “Planetary Boundaries” For Sustaining Human Civilization

Source Link: World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

Filed Under: News

Primary Sidebar

  • A Spinning Island Lake In Argentina Looms Out Of The Swamps Like An Eyeball
  • Mammals Have Evolved Into Ant Eaters 12 Times Since The Dinosaurs Went Extinct
  • Thieving Pulsar Spinning 592 Times A Second Reveals New Understanding Of Where Its X-Rays Come From
  • The Rise And Fall (And Lamentable Rise) Of The “Alpha Male” Myth
  • IFLScience The Big Questions: How Do Black Holes Shape The Universe?
  • North America’s Smallest Turtle Is The Cutest Thing You’ll Find In A Bog
  • “Unambiguous Signal” To Curb Emissions Now: Long-Lost Aerial Photos Reveal Evolution Of Antarctic Ice Shelf Collapse
  • 8 Children Have Been Born With 3 Biological Parents Each After Mitochondrial Transfer
  • First Known Observations Of Matter-Antimatter Asymmetry In Special Particle Decay
  • In 1973, NASA Sent Two Spiders Into Space To See If They Can Spin Webs – And They Learnt A Lot
  • Meet The Many Species Of Freaky Looking “Assassin Spiders” That Only Eat Other Spiders
  • Your Dog’s TV Preferences Might Reveal Their Personality
  • Some Human Gut Bacteria Can Absorb Harmful Toxic “Forever Chemicals” So They Can Be Pooped Out
  • You Could Float Through 10 Countries Before The World’s Most International River Spat You Out
  • Enormous Coronal Hole And Beast-Like Crawling Prominences Dazzle On The Active Sun
  • Dramatic Drone Footage Of Iceland’s Latest Volcanic Eruption Shows An Epic Scene From Hell
  • A Shrimp That Lives In A Tree? Indonesia’s Cyclops Mountains Are Home To Some Seriously Strange Wildlife
  • Is NASA’s Claim That Saturn Could Float On Water Really True?
  • Pangea Proxima: This Is What Planet Earth May Look Like 250 Million Years In The Future
  • The Story Of Dogxim, The Fox-Dog Hybrid That Shouldn’t Have Existed
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version